Vaccine use in primary immunodeficiency disorders

Nicola Principi, Susanna Esposito

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Primary immunodeficiency disorders (PIDs) are a heterogeneous group of rare, congenital and genetically determined conditions caused by one or more defects of innate and/or adaptive immunity. In subjects suffering from PIDs, an unusually increased susceptibility to infections is demonstrated. As infections condition the final prognosis of most PIDs, clearly defined prophylactic practices are essential. In most cases, intravenously or subcutaneously administered immunoglobulin remains the mainstay of treatment, although antibiotics and antifungals can be added under some conditions, particularly when the infections are highly recurrent despite immunoglobulin replacement. Vaccines could also play a role, but their administration leads to different results depending on the type of PID: in some cases, immune response is not impaired, and vaccines can evoke the same protection as that usually induced in healthy subjects; in others, the immunodeficiency significantly interferes with antigen stimulation of the immune system and, depending on the type and degree of impairment, little or no protection is evoked. Moreover, particularly when live vaccines are given, significant vaccine-related adverse events can occur, including the emergence of disease from vaccine strains. The main aim of this paper is to discuss what is currently known about how and when vaccines can be used in patients with PIDs in order to facilitate physician choices and assure the best possible patient protection.

Original languageEnglish
Pages (from-to)3725-3731
Number of pages7
JournalVaccine
Volume32
Issue number30
DOIs
Publication statusPublished - 2014

Fingerprint

immunosuppression
Vaccines
vaccines
immunoglobulins
Immunoglobulins
Infection
infection
Antifungal Agents
live vaccines
Adaptive Immunity
physicians
Innate Immunity
prognosis
immune system
Immune System
Healthy Volunteers
antibiotics
immune response
antigens
Physicians

Keywords

  • Bacterial vaccines
  • Primary immunodeficiency
  • Primary prevention
  • Vaccines
  • Viral vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine
  • Medicine(all)

Cite this

Vaccine use in primary immunodeficiency disorders. / Principi, Nicola; Esposito, Susanna.

In: Vaccine, Vol. 32, No. 30, 2014, p. 3725-3731.

Research output: Contribution to journalArticle

Principi, N & Esposito, S 2014, 'Vaccine use in primary immunodeficiency disorders', Vaccine, vol. 32, no. 30, pp. 3725-3731. https://doi.org/10.1016/j.vaccine.2014.05.022
Principi, Nicola ; Esposito, Susanna. / Vaccine use in primary immunodeficiency disorders. In: Vaccine. 2014 ; Vol. 32, No. 30. pp. 3725-3731.
@article{aa19ec50f38d4d53abb299ae3f4bd03d,
title = "Vaccine use in primary immunodeficiency disorders",
abstract = "Primary immunodeficiency disorders (PIDs) are a heterogeneous group of rare, congenital and genetically determined conditions caused by one or more defects of innate and/or adaptive immunity. In subjects suffering from PIDs, an unusually increased susceptibility to infections is demonstrated. As infections condition the final prognosis of most PIDs, clearly defined prophylactic practices are essential. In most cases, intravenously or subcutaneously administered immunoglobulin remains the mainstay of treatment, although antibiotics and antifungals can be added under some conditions, particularly when the infections are highly recurrent despite immunoglobulin replacement. Vaccines could also play a role, but their administration leads to different results depending on the type of PID: in some cases, immune response is not impaired, and vaccines can evoke the same protection as that usually induced in healthy subjects; in others, the immunodeficiency significantly interferes with antigen stimulation of the immune system and, depending on the type and degree of impairment, little or no protection is evoked. Moreover, particularly when live vaccines are given, significant vaccine-related adverse events can occur, including the emergence of disease from vaccine strains. The main aim of this paper is to discuss what is currently known about how and when vaccines can be used in patients with PIDs in order to facilitate physician choices and assure the best possible patient protection.",
keywords = "Bacterial vaccines, Primary immunodeficiency, Primary prevention, Vaccines, Viral vaccines",
author = "Nicola Principi and Susanna Esposito",
year = "2014",
doi = "10.1016/j.vaccine.2014.05.022",
language = "English",
volume = "32",
pages = "3725--3731",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "30",

}

TY - JOUR

T1 - Vaccine use in primary immunodeficiency disorders

AU - Principi, Nicola

AU - Esposito, Susanna

PY - 2014

Y1 - 2014

N2 - Primary immunodeficiency disorders (PIDs) are a heterogeneous group of rare, congenital and genetically determined conditions caused by one or more defects of innate and/or adaptive immunity. In subjects suffering from PIDs, an unusually increased susceptibility to infections is demonstrated. As infections condition the final prognosis of most PIDs, clearly defined prophylactic practices are essential. In most cases, intravenously or subcutaneously administered immunoglobulin remains the mainstay of treatment, although antibiotics and antifungals can be added under some conditions, particularly when the infections are highly recurrent despite immunoglobulin replacement. Vaccines could also play a role, but their administration leads to different results depending on the type of PID: in some cases, immune response is not impaired, and vaccines can evoke the same protection as that usually induced in healthy subjects; in others, the immunodeficiency significantly interferes with antigen stimulation of the immune system and, depending on the type and degree of impairment, little or no protection is evoked. Moreover, particularly when live vaccines are given, significant vaccine-related adverse events can occur, including the emergence of disease from vaccine strains. The main aim of this paper is to discuss what is currently known about how and when vaccines can be used in patients with PIDs in order to facilitate physician choices and assure the best possible patient protection.

AB - Primary immunodeficiency disorders (PIDs) are a heterogeneous group of rare, congenital and genetically determined conditions caused by one or more defects of innate and/or adaptive immunity. In subjects suffering from PIDs, an unusually increased susceptibility to infections is demonstrated. As infections condition the final prognosis of most PIDs, clearly defined prophylactic practices are essential. In most cases, intravenously or subcutaneously administered immunoglobulin remains the mainstay of treatment, although antibiotics and antifungals can be added under some conditions, particularly when the infections are highly recurrent despite immunoglobulin replacement. Vaccines could also play a role, but their administration leads to different results depending on the type of PID: in some cases, immune response is not impaired, and vaccines can evoke the same protection as that usually induced in healthy subjects; in others, the immunodeficiency significantly interferes with antigen stimulation of the immune system and, depending on the type and degree of impairment, little or no protection is evoked. Moreover, particularly when live vaccines are given, significant vaccine-related adverse events can occur, including the emergence of disease from vaccine strains. The main aim of this paper is to discuss what is currently known about how and when vaccines can be used in patients with PIDs in order to facilitate physician choices and assure the best possible patient protection.

KW - Bacterial vaccines

KW - Primary immunodeficiency

KW - Primary prevention

KW - Vaccines

KW - Viral vaccines

UR - http://www.scopus.com/inward/record.url?scp=84922249490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922249490&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.05.022

DO - 10.1016/j.vaccine.2014.05.022

M3 - Article

C2 - 24837766

AN - SCOPUS:84922249490

VL - 32

SP - 3725

EP - 3731

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30

ER -